These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 36300790)
21. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Zeña-Huancas P; Elera-Fitzcarrald C; Garcia-Hirsh S; Gil L; Pastor-Asurza CA; Rodriguez-Bellido Z; Merrill J; Askanase AD; Alarcon G; Perich-Campos RA Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33046557 [TBL] [Abstract][Full Text] [Related]
22. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488 [TBL] [Abstract][Full Text] [Related]
23. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. Rúa-Figueroa I; Rúa-Figueroa D; Pérez-Veiga N; Anzola AM; Galindo-Izquierdo M; Calvo-Alén J; Fernández-Nebro A; Sangüesa C; Menor-Almagro R; Tomero E; Del Val N; Uriarte-Isazelaya E; Blanco R; Andreu JL; Boteanu A; Narváez J; Cobo T; Bohórquez C; Montilla C; Salas E; Toyos FJ; Bernal JA; Salgado E; Freire M; Mas AJ; Expósito L; Hernández-Beriain JA; Ibarguengoitia O; Velloso-Feijoo ML; Lozano-Rivas N; Bonilla G; Moreno M; Jiménez I; Quevedo-Vila V; Pecondón A; Aurrecoechea E; Valls E; Mouriño C; Vázquez-Rodríguez T; Pego-Reigosa JM Semin Arthritis Rheum; 2022 Feb; 52():151946. PubMed ID: 35033377 [TBL] [Abstract][Full Text] [Related]
24. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151 [TBL] [Abstract][Full Text] [Related]
25. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Mok CC; Chan KL; Tse SM Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256 [TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. Sjöwall J; Azharuddin M; Frodlund M; Zhang Y; Sandner L; Dahle C; Hinkula J; Sjöwall C Front Immunol; 2021; 12():724047. PubMed ID: 34512651 [TBL] [Abstract][Full Text] [Related]
27. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Ko T; Koelmeyer R; Li N; Yap K; Yeo AL; Kent J; Pellicano R; Golder V; Kitching AR; Morand E; Hoi A Semin Arthritis Rheum; 2022 Dec; 57():152099. PubMed ID: 36155969 [TBL] [Abstract][Full Text] [Related]
36. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356 [TBL] [Abstract][Full Text] [Related]
37. Malignancy in Systemic Lupus Erythematosus (SLE) Patients. Cader RA; Mei Yee AK; Yassin A; Ahmad I; Haron SN Asian Pac J Cancer Prev; 2018 Dec; 19(12):3551-3555. PubMed ID: 30583682 [TBL] [Abstract][Full Text] [Related]
38. Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial. So H; Chow E; Cheng IT; Lau SL; Li TK; Szeto CC; Tam LS Lupus; 2022 Apr; 31(4):488-494. PubMed ID: 35254169 [TBL] [Abstract][Full Text] [Related]
39. Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus. Bruera S; Lei X; Zhao H; Yazdany J; Chavez-MacGregor M; Giordano SH; Suarez-Almazor ME Lupus Sci Med; 2023 Feb; 10(1):. PubMed ID: 36787921 [TBL] [Abstract][Full Text] [Related]
40. Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Tiseo BC; Bonfá E; Borba EF; Munhoz GA; Wood G; Srougi M; Silva CA; Cocuzza M Lupus; 2019 Jan; 28(1):59-65. PubMed ID: 30509155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]